

37TH CONGRESS OF THE ESCRS
PAVILION 7, PARIS EXPO, PORTE DE VERSAILLES
14 - 18 SEPTEMBER 2019

This Congress has been awarded 35 European CME Credits



[Register Here](#)

The additive effect of topical Nepafenac on mydriasis in patients with diabetes mellitus

Poster Details

First Author: K.Ozulken *TURKEY*

Co Author(s): M. Koc K. Tekin M. Tekin

Abstract Details

Purpose:

To evaluate the additive effect of topical nepafenac on pupil diameter (PD) in patients with diabetes mellitus (DM) and cataract.

Setting:

1. Ulucanlar eye research and training hospital 2. Tobb Etu Medical School

Methods:

Patients having cataract surgery with and without DM included in the study. Two consecutive PD measurements were taken using an automatic quantitative pupillometry system (MonPack One, Metrovision). A baseline measurement was taken, then one drop of nepafenac % 0.1 (Nevanac®, Alcon) was instilled only to the eye that will be operated on (study eye). Cyclopentolate 1.0 % (Sikloplejin®, Abdi İbrahim) was instilled to both eyes (study eye / fellow eye) five minutes later. The second measurement was taken at one hour after this application.

Results:

The DM group consisted of 43 patients while the control group of 39 patients. Baseline PDs of both eyes were similar in the DM group ($p = 0.070$) and control group ($p = 0.345$). The change in pupil size from baseline to mydriasis was statistically significantly greater in the study eyes than fellow eyes in the DM

group ($p = 0.009$) but there was no statistically significant difference in control group. PD changes were similar in the study eyes between groups ($p = 0.065$), while the PD changes in the fellow eyes were lower in the DM group ($p = 0.017$).

Conclusions:

Nepafenac has been shown additive effect on pupil dilation in diabetic patients prior cataract surgery.

Financial Disclosure:

None